Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered paper session- NSCLC, metastatic

3420 - Maintenance chemotherapy versus follow-up after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC): IFCT-1201 MODEL randomised phase 3 trial


22 Oct 2018


Proffered paper session- NSCLC, metastatic


Cytotoxic Therapy;  Cancer in Older Adults

Tumour Site


Elisabeth Quoix


E. Quoix1, C. Audigier Valette2, A. Lavolé3, O. Molinier4, V. Westeel5, F. Barlesi6, J. Le Treut7, E. Pichon8, J. Dauba9, J. Otto10, P. Dumont11, L. Moreau12, J. Madelaine13, J. Margery14, D. Debieuvre15, P.A. Renault16, A. Langlais17, F. Morin17, D. Moro-Sibilot18, P. Souquet19

Author affiliations

  • 1 Pneumologie, Hopital Civil, 67091 - Strasbourg/FR
  • 2 Pneumo, Hospital Sainte Musse, 83100 - Toulon/FR
  • 3 Pneumology, Hospital Tenon, APHP, 75020 - Paris/FR
  • 4 Pneumologie, Centre Hospitalier Du Mans, 72037 - Le Mans/FR
  • 5 Pneumologie, CHU Besançon, Hôpital Jean Minjoz, 25030 - Besançon/FR
  • 6 Medical Oncology, Aix-Marseille University - Faculté de Médecine Nord, 13015 - Marseille/FR
  • 7 Pneumologie, CH du Pays d'Aix, 13616 - Aix-en-Provence/FR
  • 8 Pneumologie, CHRU Bretonneau, 37044 - Tours/FR
  • 9 Oncologie Médicale, Centre hospitalier de Mont-de-Marsan (site Layné), 40024 - Mont de Marsan/FR
  • 10 N/a, Centre Antoine Lacassagne, Nice/FR
  • 11 Pneumologie, CH De Chauny, 2303 - Chauny/FR
  • 12 Pneumologie, Hopitaux Civils de Colmar, 68024 - Colmar/FR
  • 13 Pneumologie, CHU de Caen, 14033 - Caen/FR
  • 14 Pneumologie, HIA Percy, Clamart/FR
  • 15 Pneumologie, Hopital Emile Muller, 68100 - Mulhouse/FR
  • 16 Pneumologie, Centre Hospitalier, Pau/FR
  • 17 Clinical research Unit, French Cooperative Thoracic Intergroup, 75009 - Paris/FR
  • 18 Pneumologie, CHU Grenoble-Alpes, Grenoble/FR
  • 19 Pneumologie, Centre Hospitalier Lyon Sud, 69495 - Pierre Bénite/FR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3420


The benefit of maintenance chemotherapy with pemetrexed has been demonstrated in fit patients with metastatic lung adenocarcinoma and to a lesser extent in squamous cell carcinoma (SCC) using gemcitabine. Only few elderly patients were included in these trials. The IFCT-1201 trial is the first dedicated study to elderly patients evaluating switch maintenance chemotherapy.


We conducted a randomised trial in patients with non irradiable stage III or stage IV NSCLC (with no EGFR mutation or ALK rearrangement), aged 70-89 years, not progressing after 4 cycles of induction therapy with monthly carboplatin (AUC 6; d1, 29) and weekly paclitaxel (90 mg/m², d1,8,15, 29) comparing maintenance therapy with either pemetrexed (500 mg/m² d1, 22) in patients with non-SCC or gemcitabine (1150 mg/m² d1,8, 22) in SCC to follow-up. Second-line therapy using erlotinib was recommended in both arms. Patients were required to have a PS 0-2, a Mini Mental Score >23, and MDRD creatinine clearance >= 45 mL/min. The primary endpoint was overall survival (OS).


From May 2013 to Oct. 2016, 632 patients were enrolled: median age 76.4 (70-89), male 76%, PS 0-1 85%. After induction therapy, 328 patients were randomized (119 pemetrexed and 43 gemcitabine). Median maintenance cycles were 4 (1-38). The safety profile was as expected. Median OS (all patients from inclusion) was 11.0 months (95%CI: 9.9-12). Median OS from randomisation was 14.1 months (95%CI: 12-17) in the follow-up arm and 14 months (95%CI: 10.9-16.9) in the maintenance arm, HRa=0.91 [0.71-1.16] ; p=0.45. Progression-Free survival (PFS) was significantly longer in the maintenance arm (5.7 months (95%CI: 4.8-7.1) vs 2.7 months (95%CI: 2.6-3.1) in the follow-up arm, HRa=0.51 (95%CI: 0.4-0.64), p <0.001). Second-line therapy was administered to 103 patients (63.6%) in the maintenance arm versus 133 patients (81.1%) in the follow-up arm.


Although there was a PFS gain with the maintenance chemotherapy, this did not translate to an overall survival benefit. Switch maintenance chemotherapy should not be recommended in elderly patients with advanced NSCLC.

Clinical trial identification


Editorial Acknowledgement


This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.